Comparing success rate of three antibiotic regimes based on furazolidone, clarithromycine and levofluxacin in patients with gastric infection

Comparing success rate of three antibiotic regimes based on furazolidone, clarithromycine and levofluxacin in patients with Helicobacter pylori

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016040318124N4

Enrollment

Registered

2017-10-07

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori. Helicobacter pylori [H.pylori] as the cause of diseases classified to other chapters

Interventions

Intervention 1: First group: Tab Pantoprazole 40 mg bd /Cap Amoxicillin 1000 mg bd / Tab Clarithromycin 500 mg bd. Intervention 2: Second group: Pantoprazole 40 mg bd/Cap Amoxicillin 1000 mg bd/Tab Le

Treatment - Drugs

First group: Tab Pantoprazole 40 mg bd /Cap Amoxicillin 1000 mg bd / Tab Clarithromycin 500 mg bd.

Second group: Pantoprazole 40 mg bd/Cap Amoxicillin 1000 mg bd/Tab Levofloxacin 500 mg daily

Third group: Tab Pantoprazole 40 mg bd/Cap Amoxicillin 1000 mg bd /Tab Furazolidone 100 mg bd

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients aged 15 to 80 years; patients with dyspepsia and Peptic ulcer disease; Patients undergoing upper endoscopic procedure with positive rapid urease test (RUT). Exclusion criteria: gastrointestinal bleeding; Patients with history of taking antibiotic in last 3 weeks; taking PPI or H2 receptor antagonists in the last two week; gastric cancer; suffering from any disease needing to consume another antibiotic

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Helicobacter pylori eradication. Timepoint: 2 week after treatment. Method of measurement: Stool antigen test.	—

Secondary

Measure	Time frame
Drug reaction. Timepoint: During treatment. Method of measurement: Questioner.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazanin Gholinia

Qazvin University of Medical Sciences

nazaningholinia@yahoo.com+98 28 3376 0620

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026